

Sent By: John Forman <John@johnforman.nz> on 13/05/2016 11:14:34 a.m.
To: "ACART@moh.govt.nz" <ACART@moh.govt.nz>
Copy To:
Subject: RE: ACART consultation on the use of cryopreserved ovarian tissue to restore ovarian function

Hello to the ACART secretariat,

This is my personal submission on the consultation regarding use of cryopreserved ovarian tissue to restore ovarian function. I am happy for this submission and my name and contact details to be shared with anyone interested in the consultation.

My background involves more than 25 years of advocacy in a range of matters in health and disability, and period of 7 years, 2005 to 2011, as a member of ACART. I have a particular interest in applied ethics in health and disability services, especially in relation to equity, informed consent, and risks and benefits. Patient/consumer rights are also of great interest to me, as are the resulting duties in our health system. These interests often feature in relation to new and innovative technologies and procedures in health and disability services and research.

I agree with the advice that ACART intends to give to the minister, that use of cryopreserved ovarian tissue to restore ovarian function, should become an established procedure. I also agree that the decision is one for the woman to make in discussion with her clinician.

My detailed response is to these questions only:

Q 2. Risks.

I agree that the risks are well canvassed and that they are acceptable. This is particularly so because, by restricting the use of the preserved tissue to the woman alone, any potential risks beyond the woman and any potential child, are avoided altogether.

Q 4. Ethical issues.

I agree with the ethical analysis that supports the procedure becoming an established procedure under the provisions of the HART Act.

Regards, john

John Forman

125 Cuba St, Petone 5012

New Zealand